Virtual screening of the biological activity of fatty acid amides-Reference-Cited by-同舟云学术

Virtual screening of the biological activity of fatty acid amides

Published:2024-03-04 Issue:1 Volume:21 Page:16-25
ISSN:2524-2350
Container-title:Proceedings of the National Academy of Sciences of Belarus, Medical series
language:
Short-container-title:Vescì Nac. akad. navuk Belarusì, Ser. med. navuk

Author:

Doronkina A. S.¹,Rudak A. A.¹,Zhavoronok I. P.¹,Bogdan V. G.²

Affiliation:

1. Institute of Physiology of the National Academy of Sciences of Belarus

2. Department of Medical Sciences of the National Academy of Sciences of Belarus

Abstract

3D modeling of fatty acid amides was carried out in order to study their bioavailability indicators. Fatty acid amide complexes with the PPARα receptor were constructed by molecular docking. It was shown that fatty acid amides, based on Lipinsky’s rule of five, due to their low solubility in water, high lipophilicity and flexibility, have weak bioavailability, which limits their digestibility when taken orally. As a result of docking fatty acid amides with the PPARα receptor, stable complexes are formed. They are characterized by the presence of hydrogen bonds and a network of Van der Waals contacts.

Publisher

Publishing House Belorusskaya Nauka

Reference17 articles.

1. Treede R.-D., Rief W., Barke A., Qasim A., Bennet M. I., Benoliel R. [et al.] Chronic pain as a symptom or a disease: the IASP classification of chronic pain for the international classification of diseases (ICD-11). Pain, 2019, vol. 160, no. 1, pp. 19–27 https://doi.org/10.1097/j.pain.0000000000001384

2. Scholz J., Finnerup N. B., Attal N. J., Aziz Q., Baron R., Bennett M. I. [et al.]. The IASP classification of chronic pain for ICD-11: chronic neuropathic pain. Pain, 2019, vol. 160, no. 1, pp. 53–59. https://doi.org/10.1097/j.pain.0000000000001365

3. Forstenpointner J., Rehm S., Gierthmühlen J., Baron R. Stratification of neuropathic pain patients: the road to mechanism-based therapy? Current Opinion in Anesthesiology, 2018, vol. 31, no. 5, pp. 562–568. https://doi.org/10.1097/ACO.0000000000000642

4. Andresen S. R., Bing J., Hansen R. M., Biering-Sørensen F., Johannesen I. L., Hagen E. M., Rice A. S. C., Nielsen J. F., Bach F. W., Finnerup N. B. Ultramicronized palmitoylethanolamide in spinal cord injury neuropathic pain: a randomized, double-blind, placebo-contolled trial. Pain, 2016, vol. 157, no. 9, pp. 2097–2103. https://doi.org/10.1097/j.pain.0000000000000623

5. Vowles K. E., McEntee M. L., Julnes P. S., Frohe T., Ney J. P., van der Goes D. N. Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. Pain, 2015, vol. 156, no. 4, pp. 569–576. https://doi.org/10.1097/01.j.pain.0000460357.01998.f1